Imiject

Sumatriptan succinate, the active ingredient in Imiject, is a selective serotonin (5‑HT1B/1D) receptor agonist presented as a sterile subcutaneous injection for subcutaneous administration. It is indicated for the acute treatment of migraine attacks in adult patients, offering rapid relief of headache and associated symptoms.

GNH USA supplies Imiject as a licensed, GDP‑compliant international pharmaceutical supplier, serving hospitals, pharmacies and clinics worldwide. The company adheres to EU Good Manufacturing Practice standards and provides full regulatory documentation, cold‑chain logistics where required, and dedicated support for global procurement teams.

Sumatriptan succinate is used to treat migraine, a neurovascular headache disorder mediated by trigeminal activation and serotonin pathways.

- Migraine: provides rapid relief of headache pain and associated symptoms during an acute attack. - Migraine with aura: alleviates pain and reduces the duration of aura‑related discomfort. - Cluster headache: aborts acute cluster episodes when administered promptly.

Common Side Effects: - Chest discomfort or pressure. - Tingling or numbness in the face, neck, or extremities. - Warmth or flushing. - Nausea or abdominal discomfort. - Dizziness or light‑headedness. - Injection site pain or erythema.

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain or myocardial ischemia. - Severe hypertension or hypertensive crisis. - Serotonin syndrome, especially when combined with other serotonergic agents. - Anaphylactic or severe allergic reactions. - Persistent visual disturbances. - Acute pulmonary edema.

Before using Imiject, consider the following precautions: - Cardiovascular assessment: evaluate history of coronary artery disease or uncontrolled hypertension. - Contraindication review: avoid in patients with known hypersensitivity to sumatriptan or other triptans. - Drug interaction check: do not co‑administer with MAO inhibitors or ergot alkaloids. - Serotonergic risk: monitor for signs of serotonin syndrome when used with SSRIs, SNRIs, or other serotonergic drugs. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Sumatriptan may interact with several medication classes. Review patient medication lists carefully.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Ergot alkaloids: additive vasoconstrictive effects. - Other triptans or ergot derivatives: risk of severe vasospasm. - SSRIs, SNRIs, or other serotonergic agents: heightened serotonin syndrome potential.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure lowering. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Oral contraceptives: may slightly elevate migraine frequency. - Diuretics: monitor for changes in blood pressure.